• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20010 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Austrian Institute for Health Technology Assessment (AIHTA) Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework
2022     Austrian Institute for Health Technology Assessment (AIHTA) [Telemonitoring in Austrian diabetes care: a systematic analysis of evaluation methodologies]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Services and Delivery Research programme Components of interventions to reduce restrictive practices with children and young people in institutional settings: the Contrast systematic mapping review
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Services and Delivery Research programme Assessment and management pathways of older adults with mild cognitive impairment: descriptive review and critical interpretive synthesis
2022     Health Information and Quality Authority (HIQA) Health technology assessment of metabolic surgery for the treatment of comorbid type 2 diabetes and obesity
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tebentafusp (uveal melanoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institute for Clinical and Economic Review (ICER) Betibeglogene autotemcel for beta thalassemia: effectiveness and value
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftazidime/avibactam (bacterial infection) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institute for Clinical and Economic Review (ICER) Special assessment of outpatient treatments for COVID-19
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Imipenem/cilastatin/relebactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institute for Clinical and Economic Review (ICER) Tirzepatide for type 2 diabetes
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotrovimab (COVID-19, without supplemental oxygen, increased risk of severe disease) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - children and adolescents]
2022     NIHR Health Technology Assessment programme Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - adults]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Ontario Health Transcatheter valve-in-valve implantation for degenerated mitral or tricuspid bioprosthetic valves: a health technology assessment
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: high-dose vitamin C injections for cancer patients in Quebec]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (obesity and control of hunger in POMC, PCSK1 or LEPR deficiency obesity) - Assessment according to §35a (para. 1, sentence 11) Social Code Book VAuftraggeber: G-BA]
2022     Ontario Health Molecular testing for thyroid nodules with atypical cells of indeterminate significance
2022     NIHR Health Technology Assessment programme Outcome after selective early closure of ductus arteriosus in extremely preterm babies (Baby-OSCAR trial)
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment of hyperemesis (severe nausea during pregnancy)]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest. Update 2022
2022     Austrian Institute for Health Technology Assessment (AIHTA) Long COVID care pathways and structures: an updated scoping review
2022     NIHR Health Technology Assessment programme Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022     NIHR Health Services and Delivery Research programme Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with physical disabilities using rehabilitation services]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with intellectual disabilities (ID) or autism spectrum disorder (ASD)]
2022     NIHR Health Technology Assessment programme A randomised controlled trial of a protease inhibitor monotherapy versus continuing combination antiretroviral therapy for HIV-1 infected patients previously established on a dual nucleoside and non-nucleoside combination regimen
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of microsurgery for the prevention and treatment of cancer-related lymphedema]
2022     Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2021     Scottish Medicines Consortium (SMC) Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021     Health Information and Quality Authority (HIQA) Rapid review of public health guidance on protective measures for vulnerable groups in the context of COVID-19
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Scottish Medicines Consortium (SMC) Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021     Health Technology Wales (HTW) Strategies for Relatives (START) intervention to improve the mental health of carers of people with dementia
2021     Health Information and Quality Authority (HIQA) Rolling summary of the evidence in relation to the Omicron (B.1.1.529) variant
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     NIHR Health Technology Assessment programme A comparison of general anaesthesia versus awake-regional anaesthesia in infancy: an international, multicentre, randomised controlled equivalence trial; the GAS study
2021     Belgian Health Care Knowledge Centre (KCE) Remote monitoring of patients with cardiovascular implantable electronic devices: a health technology assessment (update of the KCE Report 136)
2021     Health Information and Quality Authority (HIQA) Use of respirator masks by persons who are at higher risk from COVID-19
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     Health Council of the Netherlands Gezondheidsraad (GR) [Influenza vaccination: review of indications]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Rebinyn (nonacog beta pegol) – Type B hemophilia (re-evaluation)]
2021     Health Information and Quality Authority (HIQA) Rapid review of public health guidance for residential care facilities in the context of COVID-19
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021     Austrian Institute for Health Technology Assessment (AIHTA) Long COVID care pathways: a systematic review
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (primary chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021     Center for Drug Evaluation (CDE) Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sodium zirconium cyclosilicate (hyperkalaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Percutaneous repair systems for tricuspid valve insufficiency by annuloplasty]
2021     Adelaide Health Technology Assessment (AHTA) Guidelines for preparing assessments for the Medical Services Advisory Committee. Version 1.0
2021     Center for Drug Evaluation (CDE) Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021     Health Technology Wales (HTW) Oscillating positive expiratory pressure devices for airway clearance in chronic hypersecretory lung conditions
2021     Adelaide Health Technology Assessment (AHTA) Immunoglobulin for chronic inflammatory demyelinating polyneuropathy
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review
2021     Adelaide Health Technology Assessment (AHTA) Genomic testing for the diagnosis of heritable cardiomyopathies
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bedaquiline (multidrug resistant tuberculosis: children aged 5 to 11 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Norwegian Institute of Public Health (NIPH) [Hysterectomy for heavy menstrual bleeding: rapid health technology assessment]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality for TAVI]
2021     Andalusian Health Technology Assessment Area (AETSA) [18F-FDG in myocardial viability for revascularization]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial nutrition in acute pancreatitis]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Addendum to commission H20-05]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Recommendations for the appropriate use of vitamin D tests and supplements in the general population]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pemigatinib (cholangiocarcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Center for Evidence-based Practice (CEP) Palliative care screening tools
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Addendum to Commission A20-105]
2021     Center for Evidence-based Practice (CEP) Procalcitonin for antimicrobial discontinuation in hospitalized adult patients
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Second addendum to commission H20-05]
2021     Center for Evidence-based Practice (CEP) Prone positioning of patients on extracorporeal membrane oxygenation (ECMO)
2021     Health Information and Quality Authority (HIQA) Duration of immunity (protection from reinfection) following SARS-CoV-2 infection
2021     Andalusian Health Technology Assessment Area (AETSA) [Clinical utility of optical coherence tomography angiography in exudative age-related macular degeneration management]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18]
2021     NIHR Health Services and Delivery Research programme Hospital-based specialist palliative care compared with usual care for adults with advanced illness and their caregivers: a systematic review
2021     NIHR Health Technology Assessment programme Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2021     Center for Evidence-based Practice (CEP) COVID-19: thrombotic adverse events with adenovirus vaccines
2021     Scottish Health Technologies Group (SHTG) The Scottish asynchronous digital dermatology appointment service (DDAS)
2021     Andalusian Health Technology Assessment Area (AETSA) [High intensity focused ultrasound (HIFU) in organ-confined prostate tumors]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atidarsagene autotemcel/OTL-200 (metachromatic leukodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     NIHR Health Technology Assessment programme Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT, DAPT plus an anticoagulant) after coronary interventions in the UK: a population based cohort study The ADAPTT Study
2021     NIHR Health Technology Assessment programme High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Process and evaluation of digital health applications in the context of "symptom-checkers"]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabotegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme EMPOWER: Early Signs Monitoring to Prevent Relapse and PrOmote Wellbeing, Engagement and Recovery
2021     Norwegian Institute of Public Health (NIPH) [Natalizumab subcutaneous for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment - health economic evaluation]